Furthermore, G‐CSF escalates pulmonary toxicity risk in synergy with other pneumotoxic agents; for instance, its role in Hodgkin's lymphoma treatment is suspected to be associated with higher bleomycin‐induced lung toxicity risk.24 Here, CSF3 is linked to Hodgkins lymphoma.